Cyclacel Pharmaceuticals (CYCCP) Announces Positive Interim Data From Phase 2 Trials of Oral Seliciclib

May 29, 2009 3:04 PM EDT

Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) announced interim data from the lead-in stage of a Phase 2 randomized clinical trial of oral seliciclib (CYC202), a novel cyclin dependent kinase (CDK) inhibitor, in patients with solid tumors and previously-treated nasopharyngeal carcinoma (NPC) at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) (Abstract 6026).

The data demonstrated that oral seliciclib could be safely administered in two dosing schedules which were well tolerated and met the criteria for proceeding to the randomized stage of the study. Seliciclib treatment resulted in prolonged stable disease in previously-treated NPC patients suggesting seliciclib inhibits tumor growth in NPC. The data supports further clinical development of oral seliciclib in NPC.

"We are pleased with these results, which met the conditions specified in the study protocol for proceeding to the next stage," said Judy Chiao, M.D., Vice President, Clinical Development and Regulatory Affairs of Cyclacel. "The results suggest that seliciclib induces prolonged stable disease and inhibits tumor growth in such patients and should be evaluated in randomized studies as a single agent and in combinations with other anti-cancer agents." [SM]

Create E-mail AlertRelated Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?